Diaceutics Plc · LSE:DXRX
Diaceutics — Investor Presentation (December 2025)
18 slides from Diaceutics's investor presentation, December 2025
Slide 1: Better Testing, Better Treatment
Better Testing, Better Treatment Corporate Overview – December 2025 Ryan Keeling | Chief Executive Officer | ryan.keeling@diaceutics.com Nick Roberts | Chief Financial Officer | nick.roberts@diaceutics.com © cop yrig ht Diaceutics 2024 2025 1 Per mission must be so ught from Diace utics if yo u wish
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”). “Presentation” means this document, any oral presentation, any question and
Slide 3: H1 2025 Highlights
H1 2025 Highlights • Revenue growth of 22% on a constant currency basis to £14.6 million in H1 2025 representing a 3-year CAGR of 25% • H1 2025 Adjusted EBITDA of £0.1 million; on track to return to full year profitability • Order book of £31.7 million with £9.0 million already contracted for H2 202
Slide 4: Operational dashboard – H1 2025
Operational dashboard – H1 2025 8 enterprise-wide 213 people inc. 74 therapeutic 43 active engagements new US sales brands customers ARR £10.1m team expansion ($13.9m) Up from 7 and 199 at Dec-24 Up from 63 in Down on 44 in £10.6m ($13.5m) H1 2024 H1 2024 at Dec-24 PMx Commercialization Partnership
Slide 5: Financial strength
Financial strength Ability to deliver exceptionally high margins through operational leverage – shift to profitability in FY 2025 Revenue CAGR >25% over past 3 years Growing ARR revenues and future revenue visibility Eight enterprise-wide engagements with blue-chip customers driving momentum Strong
Slide 6: Financial dashboard – H1 2025
Financial dashboard – H1 2025 Revenue ARR Order book value Adjusted EBITDA Cash & equivalents £14.6m £16.4m £31.7m £0.1m £10.4m Up 18% and 22% 61% recurring £9.0m already On track to Debt free & fully on a CC basis revenue in H1 2025 contracted for H2 deliver FY 2025 funded to deliver CAGR of 25% ov
Slide 7: We help pharma find patients - 3 unique assets
We help pharma find patients - 3 unique assets 1. Lab network 2. Data 3. DXRX Platform Global network of World’s largest World’s first diagnostic labs repository of commercialisation platform for healthcare data precision medicine Pharma Labs Physicians Patients • ID patients daily • ↑ Diagnostic •
Slide 8: What we do - A DXRX Signal case study
What we do - A DXRX Signal case study The result: The situation: increase in patients Client ROI: A pharma client needed to locate Upon switching on DXRX Signal in Each patient worth an average revenue of patients with a specific lung cancer week 27 of year 1 the N of patients $220k for client. With
Slide 9: What is Precision Medicine?
What is Precision Medicine? Precision Medicine (PM) is the tailoring of medical treatment to the individual characteristics of each patient – a patient’s unique genetic profile makes them susceptible to certain diseases and can influence which treatments will be safe and effective for them PM is fas
Slide 10: The Precision Medicine Challenge
The Precision Medicine Challenge PM drugs are With new PM drugs typically PM drugs are highly inherently actionable have a smaller efficacious, but it dependent on their biomarkers entering patient population, can be challenging diagnostic pathway the market making patients to provide constantly it’
Slide 11: Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution
Powered by our DXRX Platform - PMx Supercharges our Commercialisation Solution for Biopharma Launched in 2022, Signal Launched in 2024, PMx enables Biopharma sales supercharges the impact of signal team to find & engage – enabling us to engage with physicians physicians directly Direct to physician
Slide 12: PMx Enables us to Unlock Greater Value for Biopharma
PMx Enables us to Unlock Greater Value for Biopharma and Take a Larger Share of this Value •PMx V can potentially increase annual revenue per therapeutic brand from £0.4m to £3m+ Expanding our share of the Evolving our relationships from commercialisation budget vendor to partner Average revenue per
Slide 13: Significant & Growing Market Opportunity
Significant & Growing Market Opportunity Incremental Opportunity Current Status INCREASE PENETRATION IN EXISTING MARKET TAM $645m Progressing to plan Actively upsell solutions to new and existing brands within the 3-year revenue CAGR 25% 95 → 250 brands core precision medicine oncology brands to ext
Slide 14: PMx Integrates our Full Commercialisation Toolkit
PMx Integrates our Full Commercialisation Toolkit Understand Strategy Strategy Tracking Adoption the market development implementation Understand uptake Drive precision Data products Professional Scientific & medicine therapy and conversion to & professional services - to build a Engagement prescrip
Slide 15: Moving the Needle for our Customers
Moving the Needle for our Customers Delivering customer-centric excellence is critical to our strategy. This year we have achieved a 3.7/4 satisfaction score, with customers providing the following snippets of feedback: “One of our most important business “Diaceutics is front of mind for future “Cle
Slide 16: Industry Leaders in Diagnostic Commercialisation
Industry Leaders in Diagnostic Commercialisation RYAN KEELING SARAH BONDI MARIANNA SCIORTINO Chief Executive Officer & VP Data Partnerships & Strategy VP Sales Co-Founder NICK ROBERTS KEVIN ENTWISTLE MADELINE BROWN Chief Financial Officer VP Advisory Services VP Chief of Staff JORDAN CLARK KELLY WIL
Slide 17: Helping Pharma Find Patients
Helping Pharma Significant & Growing Market Opportunity Find Patients Global pharma rapidly shifting to precision medicine to target better patient care, capture lost revenue and increase profitability Growth Driven by Customer Success Strong Competitive Compelling Financial Demonstrable Advantage V
Slide 18: Team & Contacts
Team & Contacts Ryan Keeling Nick Roberts Chief Executive Officer Chief Financial Officer investorrelations@diaceutics.com Hayley Palmer | Canaccord Genuity | hpalmer@cgf.com Julie Simmonds | Panmure Liberum | julie.simmonds@panmureliberum.com Natalia Webster | RBC Capital Markets | natalia.webster@